Drug Profile
Research programme: neural stem cell therapies - ReNeuron
Alternative Names: CTX cells - ReNeuron; CTX-iPSCs; ReN 004; ReN 005Latest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator ReNeuron
- Class Neural stem cell therapies
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Huntington's disease; Neurological disorders; Parkinson's disease
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for preclinical development in Huntington's-disease in United Kingdom (Intracerebral, Implant)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Neurological-disorders in United Kingdom (Intracerebral, Implant)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Parkinson's-disease in United Kingdom (Intracerebral, Implant)